secwatch / observer
8-K filed October 30, 2023, 7:59 PM ET CIK 0001828613
M&A confidence high sentiment neutral materiality 0.85

Stem Cell Inc. acquires spinal cord injury therapy tech from related party for 2M shares; appoints Dr. Anand as CSO

Stem Cell Inc.

item 1.01item 5.02item 5.03item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Anand Kumar Arachimani

director
Stem Cell Inc.
Effective
2023-10-01
Filed
October 30, 2023, 7:59 PM ET
On October 1, 2023, the Board of Directors (the “Board”) of Stem Cell Inc. appointed Dr. Anand Kumar Arachimani as a director of the Board and Chief Scientific Officer of the Company, effective immediately.
Appointed

Dr. Anand Kumar Arachimani

Chief Scientific Officer
Stem Cell Inc.
Effective
2023-10-01
Filed
October 30, 2023, 7:59 PM ET
On October 1, 2023, the Board of Directors (the “Board”) of Stem Cell Inc. appointed Dr. Anand Kumar Arachimani as a director of the Board and Chief Scientific Officer of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Anand Kumar Arachimani was appointed as director at Stem Cell Inc..

Action
appointed
Role
director
Exact text from the filing
On October 1, 2023, the Board of Directors (the “Board”) of Stem Cell Inc. appointed Dr. Anand Kumar Arachimani as a director of the Board and Chief Scientific Officer of the Company, effective immediately.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Anand Kumar Arachimani was appointed as Chief Scientific Officer at Stem Cell Inc..

Action
appointed
Role
Chief Scientific Officer
Exact text from the filing
On October 1, 2023, the Board of Directors (the “Board”) of Stem Cell Inc. appointed Dr. Anand Kumar Arachimani as a director of the Board and Chief Scientific Officer of the Company, effective immediately.
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Stem Cell Inc.: Amended Articles of Incorporation to change company name to Stem Cell Inc (effective 2023-10-10).

Change
charter amendment
Effective
2023-10-10
Exact text from the filing
The Company has adopted an amendment to the Articles of Incorporation to effect a change of its name to Stem Cell Inc. and became effective from October 10, 2023.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Stem Cell Inc. entered into Intellectual Property Asset Transfer Agreement with Auto Stem Laboratories Private Limited (ASL) valued at two million shares of the Company’s common stock (effective 2023-10-18).

Action
entry
Agreement
asset purchase
Counterparty
Auto Stem Laboratories Private Limited (ASL)
Value
two million shares of the Company’s common stock
Effective
2023-10-18
Exact text from the filing
On October 18, 2023 the Company entered into an Intellectual Property Asset Transfer Agreement with Auto Stem Laboratories Private Limited (ASL). In accordance with the terms of the Agreement, ASL will transfer its stem cell based Spinal Cord Injury Therapy Technology to the Company for a stock consideration of two million shares of the Company’s common stock.
View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR
accession 0001477932-23-007948
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.